Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Improving Physical Ability and Cellular Senescence Elimination in HIV
NCT07144293 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Quercetin
- OTHER Placebo - Dasatinib
- OTHER Placebo - Quercetin
Study Locations (20)
California
- University of California, Los Angeles CARE Center CRS (Site ID: 601) — Los Angeles
- UCSD Antiviral Research Center CRS (Site ID: 701) — San Diego
- University of California, San Francisco HIV/AIDS CRS (Site ID: 801) — San Francisco
- Harbor University of California Los Angeles Center CRS (Site ID: 603) — Torrance
New York
- Weill Cornell Chelsea CRS (Site ID: 7804) — New York
- Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329) — New York
- Weill Cornell Uptown CRS (Site ID: 7803) — New York
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787) — Rochester
Massachusetts
- Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) — Boston
- Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107) — Boston
North Carolina
- Chapel Hill CRS (Site ID: 3201) — Chapel Hill
- Greensboro CRS (Site ID: 3203) — Greensboro
Alabama
- Alabama CRS (Site ID: 31788) — Birmingham
Colorado
- University of Colorado Hospital CRS (Site ID: 6101) — Aurora
District of Columbia
- Whitman-Walker Institute, Inc. CRS (Site ID: 31791) — Washington D.C.
Georgia
- The Ponce de Leon Center CRS (Site ID: 5802) — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144293
The ClinicalTrials.gov registry entry for NCT07144293 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with HIV appearing as the primary indexed condition, and to 4 interventions — of which Dasatinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07144293 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, New York, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07144293 about?
NCT07144293 is a clinical study titled "Improving Physical Ability and Cellular Senescence Elimination in HIV". This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living wit...
What is the current status of trial NCT07144293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-04. Estimated completion is 2026-11-29.
What conditions does trial NCT07144293 study?
This clinical trial studies the following conditions: HIV, Frailty, Aging Problems, Prefrail. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07144293?
The interventions under investigation include: Dasatinib (DRUG), Quercetin (DRUG), Placebo - Dasatinib (OTHER), Placebo - Quercetin (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07144293?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07144293 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.